Vaxart, Inc.

Firm to supply an in depth overview of its norovirus scientific program

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) immediately introduced it should host a key opinion chief video webcast on the well being and financial impression and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will characteristic shows by distinguished norovirus illness consultants Jan Vinjé, Ph.D., Head, Nationwide Calicivirus Laboratory, Facilities for Illness Management & Prevention, and Sarah Bartsch, Challenge Director, Public Well being Informatics, Computational, and Operations Analysis, Analysis Basis of the Metropolis College of New York.

As well as, Vaxart administration will present an in depth overview of the Firm’s investigational norovirus oral capsule vaccine program, together with its two present Part 2 scientific trials:

• An ongoing Part 2 GI.1 norovirus problem research measuring the efficacy and security of our norovirus vaccine candidate. The research can also be designed to establish a correlate of safety between immune responses to the vaccine and a discount in danger of norovirus an infection and / or extreme gastroenteritis. The Firm expects to report topline information from this research in Q3 2023.

• A Part 2 dose-ranging research of Vaxart’s bivalent norovirus oral vaccine candidate is designed to establish a vaccine dose for a possible Part 3 scientific trial. The Firm expects to report topline information from this research in mid-2023.

To register for the webcast, please click on right here. A replay of the webcast will probably be accessible on the Firm’s web site at www.vaxart.com following the conclusion of the occasion.

In regards to the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the Nationwide Calicivirus Laboratory and Director of CaliciNet on the Facilities for Illness Management and Prevention (CDC) in Atlanta, GA. Dr. Vinjé obtained his Ph.D. diploma on the College of Utrecht, the Netherlands, in 1999. After receiving a postdoctoral fellowship and an appointment as analysis assistant professor on the College of North Carolina in Chapel Hill, he joined CDC in 2006. Over the previous 10 years, he has served on a number of program advisory committees from a number of European analysis tasks (FP6, FP7). He’s serving as technical skilled on the norovirus subcommittee of the Nationwide Advisory Committee on Microbiological Standards for Meals and is a member of the Worldwide Committee on Taxonomy of Viruses research teams on Caliciviridae (chair as of 2014) and Astroviridae. He’s at present a member of the editorial board of the Journal of Medical Microbiology and affiliate editor of the journal Meals and Environmental Virology, and he serves as an advert hoc reviewer for a number of high-impact journals. Dr. Vinjé has printed over 100 peer-reviewed publications and a number of other ebook chapters. His analysis pursuits embody all features of viral gastrointestinal illness, together with detection, characterization, and prevention and management of norovirus infections.

Story continues

Sarah M. Bartsch, MPH
Ms. Bartsch is a Challenge Director and Senior Analyst with Public Well being Informatics, Computational, and Operations Analysis (PHICOR), the Synthetic Intelligence, Modeling, and Informatics for Diet Steering and Techniques (AIMINGS) Middle, and the Middle for Superior Know-how and Communication in Well being (CATCH), headquartered on the Metropolis College of New York (CUNY) Graduate College of Public Well being and Well being Coverage. She has been part of the group since August of 2009 and has over a decade of expertise utilizing programs approaches and creating mathematical and computational fashions to help a variety of choice makers in public well being. Bartsch has authored over 95 scientific publications, together with greater than 30 as first creator.

About Vaxart 
Vaxart is a clinical-stage biotechnology firm creating a spread of oral recombinant vaccines primarily based on its proprietary supply platform. Vaxart vaccines are designed to be administered utilizing drugs that may be saved and shipped with out refrigeration and get rid of the danger of needle-stick harm. Vaxart believes that its proprietary capsule vaccine supply platform is appropriate to ship recombinant vaccines, positioning the corporate to develop oral variations of at present marketed vaccines and to design recombinant vaccines for brand new indications. Vaxart’s growth packages at present embody capsule vaccines designed to guard towards norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), in addition to a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad home and worldwide patent purposes protecting its proprietary know-how and creations for oral vaccination utilizing adenovirus and TLR3 agonists.

Word Concerning Ahead-Trying Statements
This press launch accommodates forward-looking statements that contain substantial dangers and uncertainties. All statements, aside from statements of historic info, included on this press launch relating to Vaxart’s technique, prospects, plans and goals, outcomes from preclinical and scientific trials, commercialization agreements and licenses, and beliefs and expectations of administration are forward-looking statements. These forward-looking statements could also be accompanied by such phrases as “ought to,” “consider,” “might,” “potential,” “will,” “anticipated,” “anticipate,” “plan,” and different phrases and phrases of comparable which means. Examples of such statements embody, however will not be restricted to, statements referring to Vaxart’s skill to develop and commercialize its product candidates, together with its vaccine booster merchandise; Vaxart’s expectations relating to scientific outcomes and trial information; and Vaxart’s expectations with respect to the effectiveness of its product candidates. Vaxart could not truly obtain the plans, perform the intentions, or meet the expectations or projections disclosed within the forward-looking statements, and you shouldn’t place undue reliance on these forward-looking statements. Precise outcomes or occasions might differ materially from the plans, intentions, expectations, and projections disclosed within the forward-looking statements. Numerous vital elements might trigger precise outcomes or occasions to vary materially from the forward-looking statements that Vaxart makes.

Please additionally confer with the dangers described within the “Danger Elements” sections of Vaxart’s Quarterly and Annual Reviews filed with the SEC. Vaxart doesn’t assume any obligation to replace any forward-looking statements, besides as required by legislation.

Contacts

Investor Relations:

Andrew Blazier

FINN Companions

IR@vaxart.com

(646) 871-8486